Payment overview · 2025
General Payments
$305.42
14 reported records · 8 companies
Healthcare provider profile · identity verified
Michael Randall Keller, MD
Allopathic & Osteopathic Physicians|Family Medicine · GLENDALE, AZ · NPI 1821062183
Verified facts
What the public records show
CMS Open Payments records show Michael Randall Keller, MD received $305.42 in general payments during 2025 across 14 reported records.
Corcept Therapeutics accounted for 29.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $89.99 | 29.5% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $55.60 | 18.2% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $39.79 | 13.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.82 | 11.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.04 | 9.8% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.98 | 8.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.85 | 5.2% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.35 | 5.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $305.42 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $89.99 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $55.60 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $39.79 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $30.04 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $29.67 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.98 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.35 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.85 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 58 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
41 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
58 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 520 | 156 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 415 | 140 |
| Lisinopril | Lisinopril | 403 | 125 |
| Levothyroxine Sodium | Levothyroxine Sodium | 337 | 98 |
| Metformin Hcl | Metformin Hcl | 313 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 259 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 235 | 78 |
| Gabapentin | Gabapentin | 222 | 68 |
| Losartan Potassium | Losartan Potassium | 200 | 64 |
| Valsartan | Valsartan | 198 | 61 |
| Omeprazole | Omeprazole | 180 | 58 |
| Tramadol Hcl | Tramadol Hcl | 177 | 41 |
| Trazodone Hcl | Trazodone Hcl | 166 | 51 |
| Memantine Hcl | Memantine Hcl | 147 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 146 | 68 |
| Methylprednisolone | Methylprednisolone | 144 | 97 |
| Glimepiride | Glimepiride | 136 | 41 |
| Furosemide | Furosemide | 133 | 46 |
| Baclofen | Baclofen | 131 | 42 |
| Famotidine | Famotidine | 130 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 127 | 47 |
| Azithromycin | Azithromycin | 125 | 85 |
| Metoprolol Tartrate | Metoprolol Tartrate | 122 | 38 |
| Prednisone | Prednisone | 114 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 111 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 107 | 33 |
| Celecoxib | Celecoxib | 102 | 23 |
| Ibuprofen | Ibuprofen | 101 | 33 |
| Carvedilol | Carvedilol | 95 | 29 |
| Potassium Chloride | Potassium Chloride | 95 | 26 |
| Sertraline Hcl | Sertraline Hcl | 91 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 89 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 86 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 84 | 24 |
| Bupropion Xl | Bupropion Hcl | 79 | 22 |
| Simvastatin | Simvastatin | 79 | 19 |
| Nifedipine Er | Nifedipine | 78 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 77 | suppressed |
| Allopurinol | Allopurinol | 76 | 26 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 74 | 25 |
| Propranolol Hcl | Propranolol Hcl | 71 | 23 |
| Spironolactone | Spironolactone | 71 | 22 |
| Terazosin Hcl | Terazosin Hcl | 71 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 69 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 68 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 67 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 66 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 66 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 64 | 38 |
| Montelukast Sodium | Montelukast Sodium | 64 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 63 | 30 |
| Pregabalin | Pregabalin | 60 | 11 |
| Estradiol | Estradiol | 59 | 16 |
| Ozempic | Semaglutide | 58 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 57 | 18 |
| Clonidine Hcl | Clonidine Hcl | 54 | 18 |
| Donepezil Hcl | Donepezil Hcl | 54 | 17 |
| Atenolol | Atenolol | 53 | 17 |
| Linzess | Linaclotide | 50 | 11 |
| Ondansetron Odt | Ondansetron | 50 | 12 |
| Eliquis | Apixaban | 48 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 20 |
| Meloxicam | Meloxicam | 44 | 16 |
| Trulicity | Dulaglutide | 43 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 41 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 39 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | 13 |
| Methocarbamol | Methocarbamol | 37 | 11 |
| Lovastatin | Lovastatin | 36 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 36 | suppressed |
| Finasteride | Finasteride | 34 | 14 |
| Alendronate Sodium | Alendronate Sodium | 33 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 33 | suppressed |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Ezetimibe | Ezetimibe | 31 | 14 |
| Hydrocortisone | Hydrocortisone | 31 | suppressed |
| Jardiance | Empagliflozin | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | suppressed |
| Fluconazole | Fluconazole | 30 | 17 |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Ibu | Ibuprofen | 25 | suppressed |
| Methimazole | Methimazole | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 17 |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 16 |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 19 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Alprazolam | Alprazolam | 19 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Indomethacin | Indomethacin | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 14 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $305.42 · 14 records | Corcept Therapeutics | AIRSUPRA, BREZTRI, FREESTYLE LIBRE 3, KISUNLA, Korlym, Leqembi, Ozempic, Rybelsus, SHINGRIX, ZORYVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error